Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Pfizer Inc | 28 |
| 2 | Schroedinger Inc | 14 |
| 3 | Ono Pharmaceutical Co Ltd | 10 |
| 4 | Roche Holding AG | 9 |
| 5 | Memorial Sloan Kettering Cancer Center | 8 |
| 6 | Emory University | 7 |
| 7 | Eli Lilly and Co | 6 |
| 8 | Scripps Research Institute | 5 |
| 9 | Yale University | 4 |
| 10 | AstraZeneca PLC | 3 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 169 |
| 2 | A61K | Medicinal preparations | 142 |
| 3 | C07D | Heterocyclic compounds | 89 |
| 4 | C12Q | Measuring/testing involving enzymes | 42 |
| 5 | C07K | Peptides | 37 |
| 6 | C12N | Microorganisms, enzymes | 35 |
| 7 | G01N | Investigating / analysing materials | 28 |
| 8 | C12Y | Enzyme nomenclature (EC numbers) | 14 |
| 9 | Y02A | Climate change adaptation | 9 |
| 10 | C07B | General methods of organic chemistry | 8 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| PROTEOLYSIS TARGETING CHIMERA COMPOUNDS AND METHODS OF PREPARING AND USING SAME | 2017 | Yale University | 189 |
| Enzyme modulators and treatments | 2012 | Ono Pharmaceutical Co Ltd | 128 |
| CRYSTALLINE FORMS | 2019 | 55 | |
| ENZYME MODULATORS AND TREATMENTS | 2006 | Ono Pharmaceutical Co Ltd | 156 |
| SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | 2020 | Pfizer Inc | 43 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Anton Simeonov | National Center for Advancing Translational Sciences | 4 |
| 2 | Kelli M. Wilson | National Center for Advancing Translational Sciences | 3 |
| 3 | Matthew D. Hall | National Institutes of Health | 3 |
| 4 | Carleen Klumpp‐Thomas | National Center for Advancing Translational Sciences | 3 |
| 5 | Kyle R. Brimacombe | National Center for Advancing Translational Sciences | 3 |
| 6 | Ajit Jadhav | National Center for Advancing Translational Sciences | 3 |
| 7 | Alan J. Kraker | Warde Medical Laboratory | 3 |
| 8 | Bayard D. Clarkson | Memorial Sloan Kettering Cancer Center | 3 |
| 9 | Adam Yasgar | National Institutes of Health | 2 |
| 10 | Daniel K. Treiber | National Institutes of Health | 2 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). | 2002 | 942 | Chronic Lymphocytic Leukemia Research |
| Src activation regulates anoikis in human colon tumor cell lines | 2002 | 213 | Protein Kinase Regulation and GTPase Signaling |
| Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. | 2002 | 161 | Chronic Lymphocytic Leukemia Research |
| Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors | 2000 | 140 | HER2/EGFR in Cancer Research |
| Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. | 1999 | 120 | Microtubule and mitosis dynamics |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition and structure of PD173955?
Which organizations hold the most patents involving PD173955?
What are the major research topics associated with PD173955 publications?
How has patent activity around PD173955 evolved in recent years?
What patent classification categories are most prominent for PD173955-related patents?